View Older Stories View More Recent Stories

Jul 6, 2019 05:19AM Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World
Jun 25, 2019 08:00AM Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st
Jun 17, 2019 06:54AM Pfizer to Acquire Array BioPharma
Jun 17, 2019 06:45AM Pfizer (PFE) to Acquire Array BioPharma (ARRY) in $11.4 Billion Deal, $48/Share
Jun 17, 2019 06:45AM Pfizer to Acquire Array BioPharma
Jun 4, 2019 04:05PM Array BioPharma to Present at the Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference
May 29, 2019 04:05PM Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
May 29, 2019 11:56AM Array Biopharma (ARRY) Announces Presentation of Updated OS from Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at ASCO
May 29, 2019 11:55AM Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting
May 21, 2019 08:01AM Array Biopharma (ARRY) Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial
May 21, 2019 08:00AM Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal
May 9, 2019 04:05PM Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
May 7, 2019 08:00AM Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
Apr 30, 2019 04:05PM Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019
Mar 18, 2019 08:07AM Array Biopharma (ARRY) Announces BRAFTOVI in Combination with MEKTOVI and ERBITUX or panitumumab Recommended by NCCN Guidelines as Treatment Option for Patients with BRAF-mCRC
Mar 18, 2019 08:00AM BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatmen
Mar 5, 2019 04:05PM Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
Feb 21, 2019 04:05PM Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
Feb 5, 2019 08:00AM Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
Jan 29, 2019 04:05PM Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019
Jan 14, 2019 05:05PM Array Biopharma (ARRY) Announces 15.3 Mos. Median OS from Safety Lead-in of Phase 3 BEACON CRC Trial of Combination BRAFTOVI, MEKTOVI and ERBITUX in mCRC
Jan 14, 2019 05:03PM Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic C
Dec 20, 2018 04:05PM Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 20, 2018 04:05PM Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
Nov 6, 2018 04:05PM Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference
Oct 30, 2018 08:00AM Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019
Oct 23, 2018 04:05PM Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018
Sep 25, 2018 04:05PM Array BioPharma to Present at the 2018 Cantor Global Healthcare Conference
Sep 20, 2018 02:04PM Array Biopharma (ARRY) Says EC Approves BRAFTOVI in Combination with MEKTOVI for Advanced BRAF-mutant Melanoma
Sep 20, 2018 02:02PM European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma
Sep 13, 2018 08:07AM Array Biopharma (ARRY) Reports Publication of BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology
Sep 13, 2018 08:00AM Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology
Aug 30, 2018 04:05PM Array BioPharma to Present at the Wells Fargo Securities 2018 Healthcare Conference
Aug 14, 2018 08:00AM Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
Aug 10, 2018 08:01AM Array Biopharma (ARRY) Announces Carrie S. Cox as Board Chairman
Aug 10, 2018 08:00AM Array BioPharma Names Carrie S. Cox Chairman of its Board of Directors
Aug 7, 2018 04:05PM Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018
Aug 7, 2018 08:11AM Array Biopharma (ARRY) Receives FDA Breakthrough Therapy Designation for BRAFTOVI in combination with MEKTOVI and cetuximab for BRAFV600E-mutant mCRC
Aug 7, 2018 08:00AM Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Jul 27, 2018 08:37AM Array Biopharma (ARRY) Reports BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
Jul 27, 2018 08:30AM BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
Jul 13, 2018 08:10AM Array Biopharma (ARRY) Reports Updated Clinical Practice Guidelines from NCCN for BRAFTOVI (encorafenib) in Combination with MEKTOVI (binimetinib) as Category 1 Treatment Option
Jul 13, 2018 08:00AM The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced
Jun 27, 2018 01:48PM Array Biopharma (ARRY) Reports FDA Approval of BRAFTOVI (encorafenib) in Combination with MEKTOVI (binimetinib)
Jun 27, 2018 01:44PM Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib)
Jan 22, 2018 09:29AM Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
Jul 18, 2017 08:06AM Array Biopharma (ARRY), Array BioPharma (ARRY) Announce Pact in Inflammation
Jul 18, 2017 08:00AM Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation
May 30, 2017 06:59AM Array Biopharma (ARRY), Bristol-Myers Squibb (BMY) Enter Strategic Collaboration
May 30, 2017 06:59AM Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
View More Recent Stories View Older Stories